Role of Local Treatment for Oligometastasis: A Comparability Based Meta-Analysis

医学 优势比 荟萃分析 置信区间 内科学 随机对照试验 子群分析 科克伦图书馆 梅德林 政治学 法学
作者
Chai Hong Rim,Won Kyung Cho,Jong Hoon Lee,Young Seok Kim,Yong Jae Suh,Kyung Hwan Kim,Eui Kyu Chie,Yong Chan Ahn
出处
期刊:Cancer Research and Treatment [Korean Cancer Association]
卷期号:54 (4): 953-969 被引量:10
标识
DOI:10.4143/crt.2022.329
摘要

We intend to investigate the oncological efficacy and feasibility of local consolidative therapy (LCT) through a meta-analysis method.Four databases including PubMed, MEDLINE, Embase, and Cochrane library were searched. Target studies are controlled trials comparing outcomes of LCT versus a control group. Primary endpoints are overall survival (OS) and progression-free survival (PFS).A total of 54 studies involving 7,242 patients were included. Pooled analyses showed that the LCT arm could achieve improved OS with pooled odds ratio of 2.896 (95% confidence interval [CI], 2.377 to 3.528; p < 0.001). Regarding PFS, pooled analyses showed pooled odds ratio of 3.045 (95% CI, 2.356 to 3.937; p < 0.001) in favor of the LCT arm. In the subgroup analyses including the studies with reliable comparability (e.g. randomized studies or intentionally matched studies without significant favorable prognosticator in LCT arms), pooled odds ratio was 2.548 (95% CI, 1.808 to 3.591; p < 0.001) favoring the LCT arm regarding OS. Regarding PFS, pooled OR was 2.656 (95% CI, 1.713 to 4.120; p < 0.001) which also favored the LCT arm. Subgroup analyses limited to the randomized controlled trials (RCT) were also performed and pooled odds ratios on OS and PFS were 1.535 (95% CI, 1.082 to 2.177; p=0.016) and 1.668 (95% CI, 1.187 to 2.344; p=0.003). The rates of grade ≥ 3 complications related to LCT was mostly low (< 10%) and not significantly higher compared to the control arm.Pooled analyses results of all included studies, selected studies with reliable comparability, and RCT's demonstrated the survival benefit of LCT. These consistent results suggest that LCT was beneficial to the patients with oligometastasis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
穆奕完成签到 ,获得积分10
1秒前
ZW发布了新的文献求助10
1秒前
LLxiaolong完成签到,获得积分10
1秒前
1秒前
norman发布了新的文献求助20
1秒前
2秒前
xuluo完成签到 ,获得积分10
4秒前
ShiRz发布了新的文献求助10
4秒前
小奶瓶_发布了新的文献求助10
4秒前
风之子完成签到,获得积分10
8秒前
norman完成签到,获得积分20
12秒前
13秒前
13秒前
NexusExplorer应助ShiRz采纳,获得10
14秒前
17秒前
18秒前
19秒前
爆米花应助可可采纳,获得10
20秒前
20秒前
思源应助一个小太阳鸭采纳,获得10
21秒前
万默完成签到 ,获得积分10
22秒前
奶味蓝完成签到,获得积分10
23秒前
淼淼之锋完成签到,获得积分10
23秒前
小熊发布了新的文献求助30
23秒前
24秒前
25秒前
科研通AI5应助lynn采纳,获得10
25秒前
韩倩完成签到 ,获得积分10
25秒前
LLL完成签到 ,获得积分10
25秒前
iNk应助科研通管家采纳,获得10
26秒前
SciGPT应助科研通管家采纳,获得10
26秒前
搜集达人应助科研通管家采纳,获得10
26秒前
烟花应助科研通管家采纳,获得10
26秒前
脑洞疼应助科研通管家采纳,获得30
26秒前
李健应助科研通管家采纳,获得10
26秒前
小白完成签到,获得积分10
26秒前
无辜一一应助科研通管家采纳,获得10
26秒前
共享精神应助科研通管家采纳,获得10
26秒前
科研通AI2S应助科研通管家采纳,获得10
26秒前
852应助科研通管家采纳,获得10
27秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 3000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
Maneuvering of a Damaged Navy Combatant 650
Mindfulness and Character Strengths: A Practitioner's Guide to MBSP 380
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3776271
求助须知:如何正确求助?哪些是违规求助? 3321743
关于积分的说明 10207530
捐赠科研通 3037032
什么是DOI,文献DOI怎么找? 1666533
邀请新用户注册赠送积分活动 797517
科研通“疑难数据库(出版商)”最低求助积分说明 757868